Clinical Validation of Unani Pharmacopoeial Formulation Malerian in á¸¤ummÄ? AjÄ?miyya (Malarial Fever)

Central Council for Research in Unani Medicine CCRUM New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•1. Patients of either sex of age 18-65 years.
•2. Presence of axillary temperature >= 37.5Â°C (99.5 o F) or oral temperature of > 38 o C
•(100.4 o F) or history of fever during the past 24 hours.
•3. Mono-infection with P. vivax confirmed by either positive blood smear (i.e. no mixed
•infection) or RDT (Rapid Diagnostic Test).

•1. Any evidence of severe malaria that would require hospitalization for treatment i.e.
•including: impaired consciousness, respiratory distress, severe anaemia (Hb <5),multiple seizures, frequent vomiting/ inability to swallow tablets, prostration, jaundice,
•hypotension abnormal bleeding or hypoglycaemia. (acc. to WHO definition)
•2. Mixed or mono-infection with Plasmodium species other than P. vivax detected by
•microscopy.
•3. Patients associated with other known conditions requiring long term treatment like TB,
•AIDS, diabetes, hypertension etc.
•4. Reported allergy to any antimalarial drugs, including sulfa and artemisinin drugs.
•5. Patients with Glucose-6-phosphate dehydrogenase deficiency
•6. Pregnant and lactating females.

发起方

Central Council for Research in Unani Medicine CCRUM New Delhi